Investigación

EChiLiBRiST

Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival

Duración
Sep 2022 - Aug 2027
Coordinador
Quique Bassat
Financiadores
European Commission - Horizon Europe

EChiLiBRiST – Enhancing Children’s Lives with Biomarkers for Risk Stratification and Triage, is a consortium of 13 institutions from Europe, Africa and North America convened to develop and clinically validate a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and thus, enhance child survival.

This five year project is funded by the European Union’s Horizon Europe research and innovation programme. The project consists of two distinct yet complementary workstreams – 1) Design and validation of the device and establishing the exploitation and regulatory pathways; 2) Clinical trials and sub-studies in 3 African countries to assess the impact of the introduction of the device for risk stratification purposes, to enhance outcomes, guide management, and save costs.

The Consortium

The EChiLiBRiST consortium is led by ISGlobal and includes:

  • Eberhard Karls Universitaet Tuebingen
  • Universitat Autònoma de Barcelona
  • BioEclosion
  • Eurecat
  • Asphalion
  • Ospedale Pediatrico Bambino Gesù
  • Centro de Investigação em Saúde da Manhiça
  • Haramaya University
  • Centre de Recherches Médicales de Lambaréné
  • University Health Network
  • London School of Hygiene and Tropical Medicine
  • London School of Economics

Total funding

2.287.485,20 EUR (awarded by European Commission - Horizon Europe)

Nuestro equipo

Principal Investigator

  • Quique Bassat
    Quique Bassat ICREA Research Professor, Director del Programa de Malaria

ISGlobal team